Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus
about
Distinct genotypic profiles of the two major clades of Mycobacterium africanumThe complete genome sequence of Mycobacterium bovisEffects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathwaysPyrazinamide inhibits trans-translation in Mycobacterium tuberculosisA balancing act: efflux/influx in mycobacterial drug resistanceControl and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic SocietypncA mutations in clinical Mycobacterium tuberculosis isolates from KoreaThe Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine TuberculosisSystematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolatesA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisLearning from the past for TB drug discovery in the futureCrystal structure of the yeast nicotinamidase Pnc1pHigh-Resolution Crystal Structures of Streptococcus pneumoniae Nicotinamidase with Trapped Intermediates Provide Insights into the Catalytic Mechanism and Inhibition by Aldehydes,Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to PyrazinamideStructural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligandsStructural and Kinetic Isotope Effect Studies of Nicotinamidase (Pnc1) from Saccharomyces cerevisiaeStructural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamideEvolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, CanadaStudy of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosisThe molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosisThiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosisIn vitro antimycobacterial activity of 5-chloropyrazinamideCharacterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosisGenomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprintsThe Guinea-Bissau family of Mycobacterium tuberculosis complex revisitedRapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase methodDynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatmentMolecular dynamics simulations suggest ligand's binding to nicotinamidase/pyrazinamidaseEthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targetsCharacterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidaseBiochemical and mutational analysis of a novel nicotinamidase from Oceanobacillus iheyensis HTE831Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilliMutations in Mycobacterium tuberculosis Rv0444c, the gene encoding anti-SigK, explain high level expression of MPB70 and MPB83 in Mycobacterium bovisGenotypic analysis of the earliest known prehistoric case of tuberculosis in BritainMechanisms of Pyrazinamide Action and ResistanceMycobacterium bovis subsp. caprae Caused One-Third of Human M. bovis-Associated Tuberculosis Cases Reported in Germany between 1999 and 2001New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
P2860
Q21093332-0E98D87F-63B3-4052-85C3-095DB13FD85DQ22066275-B44A569F-2F77-4388-87FE-54B723D69D14Q24538909-A75B0F26-6EC1-49CF-BB24-E5402325D362Q24539226-FD78FCE5-C2BC-4A3E-92D3-A499EA98F596Q24609567-1A3EE072-15EB-4251-B773-B9ACBDB38ED6Q24644870-999FFCBA-0AEA-4B05-856A-B0F9D3DB8F75Q24679389-509D7292-33DC-47EB-BA2A-F8B517DE166DQ24800179-872C5BC4-7B8E-4E23-BEAF-1DA22E44F090Q26740410-726CFD65-EBDC-4A76-804D-E37E3120B052Q27004697-90C4DEC2-9560-422E-A80B-60590E23BD4DQ27011264-F7978545-0F70-401C-AAE2-EBF418E31D1DQ27485405-17B385BB-A25E-4A67-B6DC-F026B8AFC716Q27644216-82936D29-7CF8-4878-9DD9-8F8505006DF4Q27664600-84E4D883-2768-4EAC-A31B-6AB210E41AB0Q27666806-DF20DAB3-0A92-4231-9F22-E9EC2A1409BEQ27676092-95C08B2D-1461-43C7-9826-947986F3B526Q27676645-7F31743C-89D0-4F24-83FB-8403BFA7090DQ27696223-82952161-DFFD-4774-A5FE-C348220A03B6Q28083050-C90B30F0-E184-4BED-9D07-F8FEDE4BCED6Q28343917-88C4BE6D-57EF-41DD-8AA1-43F580E424D7Q28347549-4CAF8C6E-5CF2-4739-B2AF-9DB9F0B3880FQ28362898-F44F2FE5-50F5-4C6D-B76C-F1EE69C6E731Q28375163-EB9162E6-257D-4610-B386-4092D6EA17F5Q28379435-047D191E-5232-4D7B-8146-5762736DD022Q28379489-26B1A13E-215F-4127-9253-3BD0B37C2327Q28476294-D6847157-8BEE-467C-80AA-B903BEE459BCQ28477837-28F2AFB4-CC50-4F0C-B6FE-298F76A7D9A9Q28477917-49DE4735-4796-465A-8A32-7EC33F39331DQ28478602-6299F832-F3C6-453F-BF58-6D3483724278Q28480662-0F5C3DFA-5162-4BB2-9CFA-4B706708E77EQ28486213-8BCECD07-1A53-4894-A938-DA1D8C648662Q28486585-5DED651C-970A-4920-88DA-CD9BF9145252Q28486735-B8D3EC73-6C72-436D-875A-03E04D667382Q28487010-6F942817-C332-480E-8C22-122519988269Q28487200-44A2681E-741E-4B73-AC57-1BCB9C792CACQ28769635-1FBC418E-6DFE-4525-B295-670DCA2BB348Q29304444-B740BDA1-9D5F-4CE7-BC8A-427255A45BE8Q29392785-E66D6F5A-1932-45BB-8846-15F543CC089BQ30243915-46AD8E99-C6C1-4605-A28B-99339CDD9B09Q30373724-8C62C156-D0FD-4D15-99F2-A5FA8E0CFE76
P2860
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@ast
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@de
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@en
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@nl
type
label
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@ast
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@de
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@en
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@nl
prefLabel
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@ast
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@de
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@en
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@nl
P3181
P356
P1433
P1476
Mutations in pncA, a gene enco ...... azinamide in tubercle bacillus
@en
P2093
P2860
P2888
P3181
P356
10.1038/NM0696-662
P407
P577
1996-06-01T00:00:00Z